194 branded drugs lose listed protection in the next three years.
Earliest generic-entry dates for every NDA product, derived from the FDA Orange Book. Pick a year, follow a drug or company, and get an alert when a date moves.
Products losing protection by year
Branded drugs with at least one unexpired listed patent or exclusivity on a marketed reference-listed strength, by year of the earliest such expiry. Hover a year for the count.
Latest changes
All changes →- 26 Oct 2026Loperamide Hydrochloride · Generic approved 30 Sep 2026
- 26 Oct 2026Adrenalin · Generic approved 15 Sep 2026
- 26 Oct 2026Adrenalin · Generic approved 14 Sep 2026
- 26 Oct 2026Lanreotide Acetate · Generic approved 18 Sep 2026
- 26 Oct 2026Asacol Hd · Generic approved 13 Oct 2026
- 26 Oct 2026Isopto Atropine · Generic approved 16 Oct 2026
- 26 Oct 2026Renova · Generic approved 15 Sep 2026
- 26 Oct 2026Dificid · Exclusivity expires within 90 days ODE-36724 Jan 2027
- 25 Oct 2026Omnipred · Generic approved 28 Sep 2026
- 25 Oct 2026Ortho Tri-Cyclen · Generic approved 23 Sep 2026
- 25 Oct 2026Calcium Gluconate · Generic approved 17 Sep 2026
- 25 Oct 2026Bexlutry · First generic approved 21 Sep 2026